SSY Group Limited — Earnings Release 2015

Apr 30, 2015

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [308 x 113] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2015

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the three months ended 31 March 2015.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2015 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2015 increased by 2.67% as compared with the same period of 2014 to HK$487 million, with gross profit margin of 48.7% (for the three months ended 31 March 2014: 49.6%). Among which, sales of intravenous infusion solution (including the subcontracting products) for the three months ended 31 March 2015 was HK$450 million consisting of the followings:

• sales of non-PVC soft bag (excluding upright soft bag) infusion solution was HK$269 million, representing 59.8% of the sales of intravenous infusion solution and an increase of 4.9% as compared with sales for the same period of 2014;

• sales of upright soft bag infusion solution was HK$23 million, representing 5.1% of the sales of intravenous infusion solution and an increase of 1,873.2% as compared with sales for the same period of 2014;

• sales of PP plastic bottle infusion solution was HK$112 million, representing 25.0% of the sales of intravenous infusion solution and an decrease of 16.7% as compared with sales for the same period of 2014;

— 1 —

• sales of glass bottle infusion solution was HK$46 million, representing 10.1% of the sales of intravenous infusion solution and an increase of 2.1% as compared with sales for the same period of 2014.

The Group has completed the disposal of Xi’an Lijun Pharmaceutical Co., Ltd (“Xi’an Lijun”), and discontinued the operation of Xi’an Lijun since 31 October 2014. Accordingly, the Group had no results from Xi’an Lijun for the three months ended 31 March 2015. The results from Xi’an Lijun for the three months ended 31 March 2014 had been classified as a discontinued operation and thus not included in the financial information of turnover and gross profit for the same period of 2014 as announced above.

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chow Hing Yeung Company Secretary

Hong Kong, 30 April 2015

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —